Haemorrhagic cystitis (HC) is an important cause of morbidity following stem cell transplantation (SCT) and has been associated with polyoma virus infection. We studied the incidence and outcome of polyoma virus infection in 58 T-cell-depleted SCT patients. T-cell depletion was carried out using Campath-1H, either 10 or 20 mg in vitro (n ¼ 33) or 50 or 100 mg in vivo (n ¼ 25) following conventional (n ¼ 35) or nonmyeloablative conditioning (n ¼ 23). A total of 21 patients (36%) had polyoma viruria at a median of 35 days (5-114); 30% among patients receiving Campath in vitro and 44% among those given in vivo. The only risk factor for polyoma viruria was graft-versus-host disease GVHD grade X2. The onset of polyoma viruria coincided with Cytomegalovirus (CMV) reactivation in all six patients who reactivated both viruses. Prolonged viruria (defined as polyoma viruria 42 weeks) was documented in 10 patients (17%) and this was associated with GVHD Xgrade 2. HC occurred in four patients. Prolonged viruria was associated with HC only in patients receiving unrelated donor grafts following conventional conditioning. HC was not observed following nonmyeloablative conditioning despite a higher incidence of prolonged viruria. Thus, HC was uncommon in patients with polyoma viruria following T-cell depletion with Campath, particularly after reduced intensity conditioning. Bone Marrow Transplantation (2003) 31, 379-386. doi:10.1038/sj.bmt.1703847 Keywords: polyomavirus; T-cell depletion; transplantation Polyoma viruses (BK and JC viruses) are ubiquitous and 90% of children sero-convert by 10 years of age. 1 Following primary infection the virus establishes latency particularly in the kidneys. 1 They are known to reactivate during immunosuppressed states, such as solid organ transplantation, AIDS and BMT. 1 Reactivation following BMT has been reported to be associated with haemorrhagic cystitis (HC). [2] [3] [4] [5] [6] [7] [8] [9] HC is a serious post-transplant complication associated with significant morbidity. However, the relation between HC and polyoma virus remains contentious because not all patients who reactivate the virus develop HC. 10, 11 Recently, Leung et al 12 have correlated BK viruria quantitatively with the occurrence of HC. However, the impact of donor type and conditioning treatment was not apparent in this study because of small patient cohorts. It is not known whether the incidence or outcome of polyoma viruria is likely to be different after reduced-intensity conditioning. If reactivation of polyoma virus is related to a deficiency in the cellular immune system, T-cell depletion might be associated with increased virus load. Again, if higher viral load is the key factor in the occurrence of HC, then T-cell depletion should lead to an increase in the incidence of HC irrespective of the conditioning regimen. Indeed, increased morbidity and mortality have been reported with polyoma-related HC following T-cell-depleted transplants. 13 We investigated the incidence and outcome of polyoma viruria in 58 consecutive patients, Tcell depleted, with Campath in vivo or in vitro following both conventional and reduced-intensity conditioning.
Patients and methods
We evaluated 58 T-cell-depleted allograft recipients who were treated in the BMT unit at Birmingham Heartlands Hospital between June 1998 and September 2001 for evidence of polyoma virus infection. All the patients were nursed in single rooms with high-efficiency particulate air (HEPA) filters.
Conditioning treatment and T-cell depletion
All patients and donors, both related and unrelated were fully matched at both class I (A, B, C) and II loci (DR, DP, DQ). Conventional conditioning consisted of cyclophosphamide (n ¼ 23) or etoposide (n ¼ 12) and total body irradiation (n ¼ 32) or busulfan (n ¼ 3). The nonmyeloablative transplant (NMT) conditioning schedule (n ¼ 23) consisted of fludarabine and melphalan. T-cell depletion was carried out with Campath (anti-CD52) antibodies (Therapeutic Antibody Centre, Oxford). A total of 21 patients receiving conventional and four receiving NMT conditioning were transplanted from matched family (n ¼ 27) or unrelated donors (UD) (n ¼ 6) and were T-cell depleted by 10 or 20 mg Campath-1H in vitro as previously described.
14 In brief, the apheresis products were stored for a maximum of 48 h and these were pooled to a maximum volume of 500 ml. Campath-1H 20 or 10 mg was added to the final product. This was then incubated at 251C in an agitator for 30 min. The cells were immediately infused to the patient over 30-60 min.
Others (n ¼ 25) received Campath-1H in vivo. The total daily dose was administered via a syringe driver over 4 h. Recipients of UD grafts following myeloablative conditioning were treated with Campath-1H 10 mg daily for 10 days from day À5 to day +4 (n ¼ 3) or for 5 days from day -5 to day À1 (n ¼ 3). Campath-1H 20 mg/day from day À8 to day À4 was used in 19 patients receiving NMT conditioning, including six receiving UD grafts. All patients also received cyclosporin A as graft-versus-host disease (GVHD) prophylaxis from day À1.
Supportive care
Antimicrobial prophylaxis consisted of oral fluconazole, ciprofloxacin and oral aciclovir from the beginning of conditioning until engraftment. Oral co-trimoxazole was initiated when the neutrophil count was greater than 1.0 Â 10 9 /l. Metronidazole, 400 mg thrice daily was started from the day of transplant to engraftment for anaerobic decontamination as part of GVHD prophylaxis.
Study design
Virology. Stool, urine and throat samples were examined from all patients prior to transplant and weekly to fortnightly thereafter to 180 days post-transplant. Polyoma virus was detected in urine specimens by electron microscopy (EM). A volume of 20-50 ml urine was collected in an additive-free sterile container and centrifuged at 17 000 rpm for 1 h and the pellet was resuspended in 50 ml phosphate-buffered saline. For EM, a 50% v/v suspension of each centrifuged urine sample was prepared in phosphate-buffered saline and placed on EM grids with strengthened formvar membranes. The grids were stained with 2.5% phosphotungstic acid and examined using a Jeol 100CX electron microscope with an accelerating voltage of 80 kV. Direct visualization of 45 nm virus particle in urothelial cells was considered diagnostic of polyoma virus. ('Viruria' unless qualified otherwise refers to polyoma viruria in the rest of the manuscript.)
After the initial detection of polyoma virus, patients were screened more frequently so that at least one urine specimen was available every week for dipstick and virological examination. Persistent detection of polyoma virus in the urine beyond 2 weeks was termed as prolonged viruria.
The urine, stool and throat specimens were further cultured for other viruses in Hep2, rhesus monkey kidney (RMK) cells and primary liver carcinoma cell lines (PLC, Alexander cells). Cell cultures were examined for cytopathic effect for 14 days. After 180 days post-transplant, urine, stool or throat samples from symptomatic patients only were examined. The tissue samples obtained ante or post mortem were examined by EM and culture. Respiratory virus and herpes simplex virus isolates were confirmed by direct immunofluorescence using species-specific fluorescein-conjugated monoclonal antibodies (Dako Diagnostics, Cambridgeshire, UK).
Specimens for bacteriological and fungal investigations were processed using standard methods of microscopy, culture and sensitivity testing.
CMV surveillance: CMV sero-positive recipients (R) or those receiving grafts from CMV sero-positive donors (D) were defined as being at risk for CMV disease. CMV seronegative patients receiving grafts from CMV-sero-negative donors were considered as low-risk for CMV disease and these patients received CMV-negative blood products.
All the CMV at-risk patients were screened for CMV reactivation by non-nested polymerase chain reaction (PCR)-based assay (Roche, Amplicor) on whole blood collected in ethylenediamine tetra-acetic acid (EDTA). The patients were screened every week from transplant to 100 days post-transplant. Generally, those patients who had CMV infection before 100 days or had GVHD were screened for 180 days or beyond. CMV infection or reactivation was defined as PCR positivity on two consecutive assays, without clinical signs or symptoms. CMV disease was defined as demonstration of CMV by early antigen detection tests or PCR on bronchoalveolar lavage specimen in the presence of recent respiratory signs and symptoms with pulmonary infiltrates on radiology, or histological evidence of CMV from other visceral sites.
Patients received antiviral therapy if two consecutive qualitative PCR assays were positive or if CMV genome copies exceeded 400/ml on two consecutive quantitative assay. Ganciclovir 5 mg/kg b.i.d. or foscarnet 120-180 mg/ day in two or three divided doses were considered as the first-line therapy. Dose adjustments were made for impairment of renal function. Treatment was stopped if two consecutive PCR assays were negative.
Prophylaxis against HC.
Patients who received cyclophosphamide for conditioning therapy also received hydration with intravenous fluid at 3 l/m 2 /day and mesna (sodium 6 mercaptoethane sulphonate) 15 mg/kg at 0,3,6,9,12,15 and 18 h after cyclophosphamide.
Diagnosis and treatment of HC
Every urine sample was analysed by dipstick, with a sensitivity of 5-20 red cells/ml. HC was graded according to the established criteria. Grade 1, microscopic haematuria on at least two consecutive days; grade 2, macroscopic haematuria; grade 3, macroscopic haematuria with clots; grade 4, macroscopic haematuria with clots and impaired renal function secondary to urinary obstruction. Grades 1-2 HC was treated conservatively with increased fluid intake, correction of thrombocytopenia/ or coagulopathy and frequent voiding. Grades 3-4 HC were treated with continuous bladder irrigation and further cystoscopic management if necessary. Immunosuppression was reduced or withdrawn if HC was associated with polyoma viruria.
Cidofovir 5 mg/kg weekly with probenecid was used for the treatment of grades 3-4 HC with polyoma viruria if associated with polyoma viruria.
Statistical methods
The relations between the variables and viruria, prolonged viruria and HC were tested on the entire cohort and further subgroup analyse were carried out based on Campath (in vivo vs in vitro), conditioning regimen (NMT versus conventional) and GVHD (Xgrade 2). The pre and posttransplant variables were compared between the various subgroups.
Categorical variables were compared using Fisher's exact test and univariate P values and odds ratios were calculated from 2 Â 2 contingency tables using Epi info version 6 (CDC, Atlanta). The continuous variables were compared using Mann-Whitney's nonparametric method. A multiple logistic regression model was fitted to the data using a stepwise approach using the statistical programme of SPSS (SPSS version 9 for Windows, Woking, UK) for risk factor analysis if more than one variable had significant P value (o0.05).
The probability of various events was examined by the Kaplan-Meier method and the groups were compared using the log-rank test. Viruria, CMV reactivation,GVHD, HC and death were considered as time-dependent variables and the association between them was analysed in a timedependent manner. GVHD and viruria were considered to be associated if GVHD preceded or occurred within 2 weeks of viruria. CMV reactivation and viruria were considered to be coincident if both were detected on specimens taken within 7 days (as blood samples for CMV and urine specimens for polyoma virus were not always taken on the same day). Viruria was considered to be associated with HC if viruria preceded HC by at least 1 week. Non-CMV infections occurring in the first 180 days of transplant were taken into account for statistical calculations.
Results

Patient characteristics
A total of 58 patients received a T-cell-depleted transplant: 35 of them received a conventional transplant and 23 patients had NMT conditioning. Characteristics of the two groups are shown in Table 1 . The only difference between the two groups was age (median 43.7 vs 33.7, MannWhitney P ¼ 0.01) and underlying disease, with 16 patients in the NMT group being transplanted for lymphoproliferative diseases compared to only two in the conventional transplant group (Fisher's exact P ¼ 0.0001). In addition, 19/23 patients in the NMT group received Campath-1H in vivo, whereas 29/35 patients in the conventional group received Campath-1H in vitro (Fisher's exact P ¼ 0.0001).
Polyoma viruria
Polyoma viruria was detected in 21(36%) of 58 patients with a cumulative probability of 38% at 120 days. Patient characteristics are detailed in Table 2 . The median time for detection of viruria was 35 days (range 5-114 days).
Risk factors for polyoma viruria. The incidence of viruria was higher in the NMT group, although this was not statistically significant (10/23 vs 11/35, log rank P ¼ 0.3, Figure 1a) ; it is worth noting that 19 of the 23 NMT patients received 100 mg Campath in vivo. The relation between polyoma viruria and use of different doses and modes of Campath administration is shown in Figure 2 . Although the incidence was highest in patients receiving 100 mg Campath in vivo, this was not statistically significant. The incidence of grades 2-4 GVHD was similar in the NMT and conventional transplant group (Table 1) and was the only risk factor for polyoma viruria (9/21 vs 7/37; log rank P ¼ 0.05). The effect of GVHD 2-4 was more prominent among patients receiving Campath in vitro (5/7 vs 5/26; log rank P ¼ 0.003, Figure 3a and b) . However, in patients without GVHD grades 2-4, the use of Campath in vivo was associated with a higher incidence of viruria (7/16 vs 5/26; log rank P ¼ 0.06).
Overall, unrelated donor grafts were not associated with a higher incidence of viruria, but there was a trend towards an association in the conventional transplant group (6/12 vs 5/23 in related graft recipients, log rank P ¼ 0.09). In the Campath in vitro group, polyoma viruria was more common among unrelated graft recipients (4/6 vs 6/27 in related graft recipients, log rank P ¼ 0.05).
There was no association between polyoma viruria and age, gender, type of conditioning or underlying disease.
CMV and polyoma viruria. There was no effect of CMV sero-status or reactivation on polyoma viruria (Table 2) . However, in all six patients who reactivated both the viruses, the occurrence was simultaneous. In three of them, the polyoma viruria persisted after stopping anti-CMV therapy. There was no relation between coincident reactivation of the two viruses and conditioning treatment.
The majority of the patients with polyoma viruria had another non-CMV viral infection ((17/21 vs 9/37; odds ratio 4.4, 95% CI 1.1-18.4); Fisher's exact P ¼ 0.001). This difference was more marked for herpes viruses (Table 2) .
Prolonged polyoma viruria. Prolonged polyoma excretion (42 weeks, range 3-14) was noted in 10 patients. This was again more common in patients with GVHD grades 2-4 (6/16 vs 4/42; log rank P ¼ 0.01) and more so in the Campath in vitro group (4/7 vs 1/26; log rank P ¼ 0.001). Again, this was more frequent in the NMT group, but was not statistically significant (5/23 vs 5/35, log rank P ¼ 0.4, Figure 1b ). Simultaneous CMV reactivation was also associated with prolonged viruria (3/6 vs 7/52; log rank P ¼ 0.01).
There was no association between prolonged viruria and age, gender, type of conditioning or underlying disease, In addition, no risk factors for prolonged viruria were identified on subgroup analysis in NMT and conventional transplant recipients.
Haemorrhagic cystitis. HC was recorded in four patients (6.8%). Three had grades 3-4 HC and one had grade 2. Three of these patients had prolonged polyoma viruria, and viruria preceded HC in all instances by at least 2 weeks. Thus, 14% of the patients with viruria had HC, and prolonged viruria was a risk factor for HC (3/10 vs 1/48; log rank P ¼ 0.01).
Despite a higher cumulative incidence of prolonged viruria, none of the NMT recipients had HC, compared to 4/35 recipients of conventional conditioning (12% probability log rank P ¼ 0.09, Figure 1c) .
HC occurred exclusively in UD graft recipients (4/18 vs 0/40; log rank P ¼ 0.001) and only in those conditioned conventionally with cyclophosphamide (4/23 vs 0/35; log rank P ¼ 0.02). On subgroup analysis in the conventional transplant recipients, UD grafting was still strongly associated with HC (4/12 vs 0/23 in related transplants, log rank P ¼ 0.001) and cyclophosphamide conditioning had borderline significance (4/23 vs 0/12 in conventional conditioning without cyclophosphamide, log rank P ¼ 0.09).
Prolonged viruria in UD transplants had a 75% probability (Figure 4a ) of being associated with HC, and in those receiving cyclophosphamide it was 100% (Figure 4b) . Thus, HC occurred only in UD graft recipients following conventional cyclophosphamide-based conditioning and in association with prolonged polyoma viruria.
One patient with grade 2 HC and another with grade 3 HC improved with conservative treatment and reduction of steroid dose in the former, and cyclosporine in the latter. A 21-year-old man with grades 3-4 HC was treated with single dose of cidofovir as he was receiving steroids for GVHD. This was associated with clinical improvement, although the viruria persisted until the dose of steroids was reduced. The fourth patient had grade 4 HC without viruria and required surgical intervention. in vivo (b) . The solid line (------) represents patients with grades 2-4 GVHD ((a) events 5/7, probability 71.5%, 95% CI 38.2-100; (b) events 4/9, probability 50%, 95% CI 23.6-86.4). The broken line (------) represents patients with grades 0-1 GVHD ((a) events 5/26, probability 20%, 95% CI, 4.4-35.6; (b) events 7/16, probability 45%, 95% CI 20.2-69.8). The difference was significant with log rank P ¼ 0.003 for Campath in vitro (a) and not significant with log rank P ¼ 0.9 for Campath in vivo (b).
All the patients with prolonged viruria without HC ceased to have viruria when cyclosporine/ or steroids was reduced or withdrawn. In one patient with viruria for 14 weeks and simultaneous isolation of adenovirus from stool, cessation of viruria followed donor lymphocyte infusion (DLI) for relapsed leukaemia.
Survival. The overall survival at 2 years in patients with and without polyoma viruria was 62.4% (95% CI 40-82) and 54.3 (95% CI 36.2-72.4). The nonrelapse mortality was also similar in patients with and without polyoma viruria (37.2, 95% CI 17.1-57.3 versus 33.9, 95% CI 19.6-48.1).
Discussion
In this study, the cumulative incidence of polyoma viruria was 38%. Using sensitive techniques such as PCR, almost all stem cell transplant recipients have been found to have polyoma viruria. 11, 12 Given the oversensitive nature of the qualitative PCR assay, quantitative PCR is the best diagnostic modality for following the kinetics of viral load. 12 EM is considered to be the gold standard for diagnosis of polyoma virus, although it does not differentiate between BK and JC viruses. 1 In addition, EM is unlikely to detect low viral loads, as the threshold for detection by EM is 10 6 -10 7 viruses/ml. In one study, only 30% of the samples positive for BK virus on nonquantitative PCR were detected by EM. 5 It is thus understandable that on using different diagnostic modalities, the detection rate of viruria is likely to be different. Despite the lower sensitivity of EM, the incidence of polyoma viruria was significant in our cohort.
Polyoma viruria was associated with the severity of immunosuppression. It was related to the severity of GVHD and in patients without GVHD, there was a significant association with the dose of Campath. As T-cell depletion was carried out using Campath antibodies alone, we were able to demonstrate a correlation between the dose and mode of Campath and the incidence of polyoma virus infection. Pharmacokinetic studies have demonstrated that this antibody was detectable at a higher level for longer duration after transplant when used in vivo 15 . Thus, the difference noted by us between the patients receiving 50-100 mg in vivo and those transplanted with grafts treated with 10-20 mg Campath in vitro, reflected not only the extent of T-cell depletion of the graft, but also the kinetics of T-cell recovery. As a surrogate for increased immunosuppression, the viruria group had an increased incidence of non-CMV viral infection. At this higher detection threshold, we tried to look at the subgroup of patients who had persistent excretion of polyoma virus. This was again more common in patients with GVHD 4 grade 2.
However, despite detecting viruria in 36% of patients, the overall incidence of HC was only 6.4%. None of the patients receiving nonmyeloablative conditioning had HC, irrespective of the type of graft and prolonged viruria. Also, patients receiving transplants from family donors had no HC despite prolonged viruria. Prolonged viruria was only associated with HC in recipients of UD grafts who received cyclophosphamide-based conventional conditioning. As the NMT recipients did not receive cyclophosphamide in their conditioning treatment, it remains unclear whether a similar or a lower dose of cyclophosphamide used in a nonmyeloablative setting would have a parallel impact. However, the NMT conditioning protocol that we have employed does not seem to be associated with HC, even in the presence of prolonged viruria.
HC occurring very early after transplant is related directly to the conditioning treatment, but late-onset HC is less well understood. A recent study suggested increasing . The solid line (------) represents patients with prolonged viruria ((a) events 3/4, probability 75%, 95% CI 32.7-100; (b) events 3/3, probability 100%). The broken line (------) represents patients without prolonged viruria ((a) events 1/14, probability 8.4%, 95% CI 0-23.8; (b) events 1/20, probability 6.3%, 95% CI, 0-16.3). The difference was significant with log rank P ¼ 0.001 for unrelated donor grafts (a) and log rank P ¼ 0.0001 for cyclophosphamide conditioning (b). viral load as the only cause for HC. 12 We did not quantitate the viruria, but prolonged viruria by itself did not seem sufficient to cause HC. GVHD has also been identified as a risk factor for polyoma-associated HC in previous studies. 9, 14 Although viruria, both short-lived and prolonged, was related to GVHD in our study, this was largely mild with only two patients experiencing grade 3 and none grade 4 GVHD. Both grade 3 GVHD episodes and prolonged viruria were in nonmyeloablative transplant recipients and none of the UD graft recipients receiving nonmyeloablative conditioning had HC despite prolonged viruria. Based on these observations, it is reasonable to hypothesize that HC occurs as a result of the interplay between several factors and the intensity of conditioning treatment has a role to play.
HC is probably an immunological assault directed at the bladder mucosa by the immunocompetent T-cells of donor origin in response to persistent viral incitement. The adequate proinflammatory milieu is created by the damage to the bladder mucosa because of intensive cyclophosphamide-based conditioning, making the organ more susceptible to immune-mediated injury. This immunological damage may be greater in a UD graft recipient and in the presence of severe GVHD. Based on this hypothesis, it might be extrapolated that if the graft is T-cell depleted, even in the presence of viruria and other proinflammatory factors, damage to the bladder mucosa might be much attenuated. While other methods of T-cell depletion resulted in a high incidence of polyoma-related HC, this was not the case with the use of Campath antibodies in our study. It is possible that the extended action of Campath on antigen-presenting cells 16 was associated with further dampening of the inflammatory triggers. However, in the absence of these additional factors, viruria may be innocuous as far as its effect on the bladder mucosa is concerned particularly if grafts are T-cell depleted with Campath.
Previous case reports have suggested a relation between CMV and polyoma reactivation. 17 This is the first time this has been demonstrated in a prospective study. In half of the patients, virus excretion subsided with achievement of CMV-PCR negativity, and in the other half it persisted for several weeks after this had been achieved. However, there was no increase in CMV disease or HC in this subgroup showing concomitant reactivation. While it is possible that CMV induces replication of polyoma virus, 18 this, again, was not sufficient to trigger HC in these patients. None of these six patients had received a UD graft following cyclophosphamide-based conventional conditioning. Two of the three patients with prolonged viruria in this group had received reduced-intensity conditioning and the third received etoposide-based conditioning. It is also worth noting that in this study, the majority of the conventional UD transplant recipients were at low risk of CMV disease.
There is no established antiviral treatment for polyomarelated HC. Vidarabine has been tried occasionally with variable success. 19, 20 Cidofovir has been shown to have selective antipolyomavirus activity in vitro. 21 Its efficacy in the clinical setting has been reported in two case reports. 22, 23 We used cidofovir in one patient for a single dose and this was associated with clinical improvement. However, a virological response in this patient and others occurred only after the reduction of immunosuppression. Interestingly, in one patient with viruria for 14 weeks, this cleared after DLI for relapsed leukaemia. 24 Lymphoproliferative responses to polyomaviruses has been demonstrated in post-BMT patients 25 and our observations seem to suggest that the virus is susceptible to cellular immunity.
Reduction of immunosuppression in high-risk patients, for example, UD graft recipients following conventional cyclophosphamide-based conditioning, could be the first step in the treatment algorithm for polyoma-related HC. If immunosuppression cannot be withdrawn, antiviral therapy could be tried. This can be either cidofovir or vidarabine and because of the paucity of controlled studies, the efficacy of these agents remains unproven. It is important to stem the process at an early stage, either pre-emptively or at the earliest sign of HC, as antiviral therapy might not have a major impact in the face of severe HC. Although the use of donor lymphocytes could be worth pursuing, this is attached to the risk of generating GVHD and might actually worsen the situation if used late in the course of the events.
In conclusion, polyoma viruria was more common in patients with GVHD, and in the absence of GVHD, in those receiving Campath in vivo. Polyoma-associated HC was not observed among patients receiving reducedintensity conditioning, despite a high incidence of viruria. Prolonged polyoma viruria was associated with HC only in UD graft recipients following cyclophosphamide-based conventional conditioning. In view of the susceptibility of polyomavirus to cellular immunity, reduction of immunosuppression with or without cidofovir therapy might be used as pre-emptive or early therapy for polyomaassociated HC.
